Devraj Srinivasan

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.6K citations · Full text

Medicine, Pathology, Head And Neck Cancer +5

Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial

Hisham Mehanna, Max Robinson, A. Hartley et al. · The Lancet · 2018 · 988 citations · Full text

Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial

Christopher M. Nutting, Laura Finneran, Justin Roe et al. · The Lancet Oncology · 2023 · 93 citations · Full text

Tyrosine Kinase Inhibitor Therapy in Locally Advanced Differentiated Thyroid Cancer: A Case Report

Kirsten Stewart, Mark W. J. Strachan, Devraj Srinivasan et al. · European Thyroid Journal · 2019 · 38 citations · Full text

Surgical Oncology, Surgery, Oncology +21

Results of a randomized phase III study of dysphagia-optimized intensity modulated radiotherapy (Do-IMRT) versus standard IMRT (S-IMRT) in head and neck cancer.

Christopher M. Nutting, Keith Rooney, Bernadette Foran et al. · Journal of Clinical Oncology · 2020 · 32 citations

Surgical Oncology, Neck Cancer, Tonsillectomy +22